CRISPR Babies: Eugenics, Ethics, and Why Regulation Efforts Could Be Too Late | Jennifer Doudna
July 8, 2017
31,834
625
237
2.71%
Search the Record
IndexedEvery word spoken in this episode is indexed. Type any phrase to jump straight to the moment it was said.
Type any word or phrase that may have been spoken. Click a result to seek the player to that exact moment.
Try a name, a topic, or a quoted line
Big Think Episodes Around July 8, 2017
See what was published immediately before and after this episode.
2:32Now PlayingCRISPR Babies: Eugenics, Ethics, and Why Regulation Efforts Could Be Too Late | Jennifer Doudna
YouTube Description
as posted by the channelCRISPR Babies: Eugenics, Ethics, and Why Regulation Efforts Could Be Too Late
Watch the newest video from Big Think
Join Big Think Edge for exclusive videos
----------------------------------------------------------------------------------
Can genetic engineering be regulated? Better question: should it be regulated? Jennifer Doudna, the co-creator of genetic engineering tool CRISPR, thinks that the answer isn't easy. Corporate interests could change everything, as could the desires of a madman if CRISPR were to fall into the wrong hands. But Doudna is happy that people are talking about the best ways to regulate the technology this early in the game as it's the kind of thing that could truly reshape the human race. Should we be concerned? Frankly, no. But we should remain vigilant that CRISPR gets used correctly and not for a future Westworld-esque scenario.
Jennifer Doudna's most recent book is "A Crack in Creation: Gene Editing and the Unthinkable Power to Control Evolution"
.----------------------------------------------------------------------------------
JENNIFER DOUDNA:
Jennifer A. Doudna, Ph.D., Professor of Molecular and Cell Biology and Chemistry at the University of California, Berkeley, has devoted her scientific career to revealing the secret life of RNA. Using structural biology and biochemistry, Doudna's work deciphering the molecular structure of RNA enzymes (ribozymes) and other functional RNAs has shown how these seemingly simple molecules can carry out the complex functions of proteins.
Doudna is a pioneer of the revolutionary CRISPR/Cas9 gene-editing technology. Working with microbiologist Emmanuelle Charpentier, postdoctoral researcher Martin Jinek and graduate student Krysztof Chylinski, the team published their findings in Science in August 2012. Their paper immediately and dramatically transformed the field of molecular biology and genetics. Since then, Doudna and other scientists have shown that the CRISPR/Cas9 technique works in human cells, a finding with enormous implications for preventing and treating many intractable diseases, including viral illnesses, such as HIV, and genetic conditions, such as Down syndrome and sickle cell anemia.
Jennifer Doudna is the author of A Crack in Creation: Gene-Editing and the Unthinkable Power to Control Evolution.
----------------------------------------------------------------------------------
TRANSCRIPT:
Jennifer Doudna: Well, when we think about designer humans or “CRISPR babies” as we've seen in the media, this sparks some people's imagination to think about what one might want to do with a technology like this, maybe not today and maybe not next year but in the future.
And it's one thing to talk about being able to remove mutations from the human population that cause genetic disease—and I think for many people that would be a desirable thing to do—On the other hand I think it's a very different discussion to think about using a technology like this to create enhanced human beings, people that are taller or have a certain eye color or other kinds of physical or intellectual traits that might be considered desirable.
And it sort of immediately brings up sort of the whole area of eugenics and sort of access to technology, who gets access, who pays for it, who decies? Who decides whether or not to do such a thing? Should companies be allowed to offer this as a service to parents who want to do this so should they be regulated in some way? There's a lot of very interesting and challenging questions I think that go along with that. And then there's the whole question of, since this is a technology that is widely available—I really call it a democratizing technology because it's not very expensive to use and labs worldwide have been able to easily deploy it in different systems—So then how do we think about a global regulation?
Is it even possible to come to some kind of consensus globally? I'm not sure, honestly, of the answer to that.
I think that it's certainly important to be having this discussion with our colleagues in other countries and fortunately that's happening.
But are we going to be able to control what people are doing in every jurisdiction? I think no way, and so I think it's one of those things that it's one of the aspects of this technology that we have to grapple with, is the fact that it's widely available and that people will start using it in different ways, potentially even in the future to create genetically altered humans.
Links & Promotions
Guests & Subjects Covered
Sentinel Indexing in Progress
Metadata and chapters are available. Claim extraction for this episode is pending.
All video content is delivered via YouTube embedded players in accordance with the YouTube Terms of Service. Sentinel provides research tools that promote discovery and accountability across political media.









